Literature DB >> 22233555

Emerging therapies for thyroid carcinoma.

S Walsh1, R Prichard, A D K Hill.   

Abstract

Thyroid carcinoma is the most commonly diagnosed endocrine malignancy. Its incidence is currently rising worldwide. The discovery of genetic mutations associated with the development of thyroid cancer, such as BRAF and RET, has lead to the development of new drugs which target the pathways which they influence. Despite recent advances, the prognosis of anaplastic thyroid carcinoma is still unfavourable. In this review we look at emerging novel therapies for the treatment of well-differentiated and medullary thyroid carcinoma, and advances and future directions in the management of anaplastic thyroid carcinoma.
Copyright © 2011 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22233555     DOI： 10.1016/j.surge.2011.08.004

Source DB:  PubMed          Journal:  Surgeon        ISSN： 1479-666X            Impact factor:   2.392


  6 in total

1.  Anaplastic Spindle Cell Squamous Carcinoma Arising from Tall Cell Variant Papillary Carcinoma of the Thyroid Gland: A Case Report and Review of the Literature.

Authors:  Darren K Patten; Alia Ahmed; Owain Greaves; Roberto Dina; Rashpal Flora; Neil Tolley
Journal:  Case Rep Endocrinol       Date:  2017-04-06

2.  NVP-BEZ235 inhibits thyroid cancer growth by p53- dependent/independent p21 upregulation.

Authors:  Banjun Ruan; Wei Liu; Pu Chen; Rongrong Cui; Yu Li; Meiju Ji; Peng Hou; Qi Yang
Journal:  Int J Biol Sci       Date:  2020-01-14       Impact factor: 6.580

3.  Micro-RNA-451 Reduces Proliferation of B-CPAP Human Papillary Thyroid Cancer Cells by Downregulating Expression of Activating Transcription Factor 2.

Authors:  Mei-Feng Zhang; Zhe-Wei Fei; Lei Huang
Journal:  Med Sci Monit       Date:  2021-03-16

4.  Overexpression of PAX8-AS1 Inhibits Malignant Phenotypes of Papillary Thyroid Carcinoma Cells via miR-96-5p/PKN2 Axis.

Authors:  Ping Zhou; Tongdao Xu; Hao Hu; Fei Hua
Journal:  Int J Endocrinol       Date:  2021-10-26       Impact factor: 3.257

5.  Clinical Efficacy of Levothyroxine Sodium plus I 131 in the Treatment of Patients with Thyroidectomy and Its Effect on the Levels of Thyroglobulin and Thyrotropin.

Authors:  Ya-Ling Pang; Yan-Ping Wang; Kun Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-02       Impact factor: 2.650

6.  Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.

Authors:  Serena Giunti; Alessandro Antonelli; Andrea Amorosi; Libero Santarpia
Journal:  Int J Endocrinol       Date:  2013-02-21       Impact factor: 3.257
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.